The addition of inotuzumab ozogamicin to conditioning for alloSCT in ALL and lymphoid malignancies

Issa Khouri, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study investigating the addition of inotuzumab ozogamicin to a reduced-intensity conditioning regimen for allogeneic stem cell transplantation (alloSCT) for patients with acute lymphoblastic leukemia (ALL) and aggressive lymphoid malignancies. Dr Khouri reports encouraging results, with no risk of veno-occlusive disease and a promising overall survival rate of 62% at three years and 14% treatment-related mortality at two years. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.